Form 8-K - Current report:
SEC Accession No. 0001558370-22-012525
Filing Date
2022-08-08
Accepted
2022-08-08 08:05:24
Documents
15
Period of Report
2022-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ganx-20220808x8k.htm   iXBRL 8-K 35260
2 EX-99.1 ganx-20220808xex99d1.htm EX-99.1 216082
3 GRAPHIC ganx-20220808xex99d1002.jpg GRAPHIC 6627
  Complete submission text file 0001558370-22-012525.txt   407823

Data Files

Seq Description Document Type Size
4 EX-101.SCH ganx-20220808.xsd EX-101.SCH 3753
5 EX-101.DEF ganx-20220808_def.xml EX-101.DEF 2841
6 EX-101.LAB ganx-20220808_lab.xml EX-101.LAB 18022
7 EX-101.PRE ganx-20220808_pre.xml EX-101.PRE 10725
9 EXTRACTED XBRL INSTANCE DOCUMENT ganx-20220808x8k_htm.xml XML 4982
Mailing Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814
Business Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814 (301) 500-1556
Gain Therapeutics, Inc. (Filer) CIK: 0001819411 (see all company filings)

EIN.: 851726310 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40237 | Film No.: 221142623
SIC: 2834 Pharmaceutical Preparations